Details
Intas Pharmaceuticals Ltd.
| Description: | Headed by a strong pool of 400+ scientists and researchers, R & D is the key growth driver for Intas. Its constant quest for developing new products and technology has led breakthrough innovations in a wide spectrum of areas such as Oncology, hormones & NDDS, apart from other generic products. Till date, Intas has filed 50+ patents on novel formulations, API polymorphs/processes & analytical methods to its credit.Intas continuous R & D initiatives have strengthened its product basket with delivery of niche and complex products. Intas is extensively working on Para IV and 505 (b) 2 products for USA market and few products are already filed with USFDA. Intas targets to file more than 5 Para IV applications to US market each year.Intas Pharmaceuticals is engaged in research, development and commercialization of novel therapeutic products for the treatment of cancer, infectious diseases and acute medical emergencies. The company in collaboration with US based Jina Pharmaceuticals Inc. has developed a clinically validated proprietary Nanoaqualipâ„¢ technology to formulate drug products. The newly formulated drugs are less toxic with improved bioavailability and better therapeutics. Based on Nanoaqualipâ„¢ technology the company is enhancing broader applications of generic drugs, difficult to formulate drugs and drugs of which the patent rights are near expiration through the development of improved delivery system.Intas is actively involved in the development and commercialization of biologics. Since inception, 8 biologics have been commercialized in India and around 15 biologics are at different stages of development. The highly qualified and capable R&D, focuses on the biosimilar product development keeping the European and the US Regulatory guidelines in the view. One of the assets is under registration with the EU authority and another at advanced stage of clinical development in the European region.The company is also focused on discovery and development of New Chemical Entity (NCEs) targeting cancer and neurodegenerative diseases such as bipolar disorder. The molecule has completed Phase-Ib Clinical Studies & entering into Phase-II Efficacy Studies.Intas R & D strategies are focused on 2 major areas:1. Pharmaceutical Formulation DevelopmentIntas primary focus area in formulation development includes:
Platform Technologies Microspheres Microsphere technology is aimed at developing formulations providing controlled release of therapeutically active compounds. Microspheres are engineered for controlled release depot injections targeted for drug release from one month up to six months.We have highly sophisticated and fully equipped labs for the development of microspheres and capability to up-scale the process for commercial manufacturing. Liposomal Technology Liposomal technology is one of the key tools developed by Intas to address the challenges of undesirable physiochemical properties of drugs which lead to poor pharmacokinetics.Liposomomal formulations developed in Intas have displayed capability to incorporate hydrophilic and hydrophobic drugs, good biocompatibility, low toxicity, lack of immune system activation, and targeted delivery of bioactive compounds to the site of action. Sustained Release Formulation Technology The expertise gathered over the decades of experience in formulation sciences has led to the development of several sustained release products. The sustained release products are helpful in reducing dosing frequency to an extent that once daily dosing is sufficient for therapeutic management through uniform plas |
| Address: | Chinubhai Centre, Off. Nehru Bridge, Ashram Road, Ahmedabad - 380009. Gujarat. India. |
|
|